• Second clinical trial site activated, enabling patient enrolment
• Trial will provide safety, tolerability and pharmacokinetic data on RC220
• Optimal dosage of RC220 with doxorubicin to be assessed in Stage 2

Race Oncology Ltd has announced the activation of the second site for patient enrolment for its Phase 1 clinical trial of RC220, in combination with doxorubicin, in patients with advanced solid tumours. The new site is the Central Coast Local Health District (Gosford and Wyong Hospitals), following the earlier activation of the lead Australian site, Southside Cancer Centre in Miranda, NSW. The open-label, Phase 1 trial will be conducted at multiple sites across Australia, Hong Kong and South Korea. The Phase 1 trial will use ascending doses of RC220 in up to 33 patients in Stage 1 to determine its safety, tolerability, pharmacokinetics, maximum tolerated dose in combination with doxorubicin (MTCD), and effects on a range of clinical biomarkers including m6A RNA. After an interim analysis, the optimal dosage of RC220 in combination with doxorubicin will be assessed in an additional 20 patients in Stage 2 for further safety, tolerability, and preliminary cardioprotective and anticancer efficacy signals. Race Oncology's CEO, Dr Daniel Tillett, commented that the activation of the second site will accelerate patient recruitment and the collection of critical data.

Race Oncology is advancing the clinical development of RC220 to address the high unmet needs of patients across multiple oncology indications, with a focus on anthracycline combinations, where the company hopes to deliver cardioprotection and enhanced anticancer activity in solid tumours. The company is also exploring RC220 as a low-intensity treatment for acute myeloid leukaemia.